Equity Overview
Price & Market Data
Price: $1.55
Daily Change: -$0.09 / 5.81%
Daily Range: $1.50 - $1.61
Market Cap: $9,663,534
Daily Volume: 41,589
Performance Metrics
1 Week: 6.08%
1 Month: -8.72%
3 Months: -42.49%
6 Months: -57.24%
1 Year: -77.82%
YTD: -4.85%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country:
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.